84.4% of the cancer patients taking ivermectin + mebendazole reported no evidence of disease, tumor regression, or cancer stabilization after 6 months.
That kind of signal doesn’t happen randomly. The key question is not just what we observed, but why.
There are now hundreds of preclinical studies—in both cell systems and animal models—showing that antiparasitic agents like ivermectin and mebendazole exert broad, multi-target anti-cancer effects across more than a dozen tumor types.
https://open.substack.com/pub/petermcculloughmd/p/844-of-cancer-patients-taking-ivermectin